Poxel Reports Financial Results for First Half 2023 and Provides a Corporate Update

LYON, France, September 26, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.

Related Keywords

Paris ,France General ,France ,New York ,United States ,Boston ,Massachusetts ,Japan ,China ,Tokyo ,India ,Illinois ,French ,Japanese ,Khoso Baluch ,Merck Serono ,Sumitomo Pharma ,Manavarere Arthur Rouill ,Thomas Kuhn ,Sophie Bozec ,Nicolas Fossiez ,Financial Press ,European Patent Office ,Community Weekend ,International Meeting ,Alex Leukodystrophy Charity ,Meeting Of The Japanese Diabetes Society ,United Leukodystrophy Foundation Scientific Symposium ,Company Universal Registration Document ,Us Patent Office ,Regulatory News ,Chief Executive Officer ,Imeglimin Phase ,Annual Meeting ,Japanese Diabetes Society ,Long Term Study ,Japanese Type ,Renal Impairment ,United Leukodystrophy Foundation ,Scientific Symposium ,Family Conference ,Poxel Senior Vice President ,Scientific Communication ,Pascale Boissel ,French State ,Universal Registration ,Following Upcoming ,Innovation Days ,Healthtech For Care ,Financial Press Release ,Third Quarter ,Corporate Update ,Euronext Paris ,Fiscal Year ,Arthur Rouill ,Troxel ,Fy 2023 ,Gross Sales ,